A Phase 2 interventional study of MEDI9929 and Placebo in Atopic Dermatitis, sponsored by MedImmune LLC. Completed at 29 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-02-15.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 251st largest by enrollment of the 544 interventional ones that give a count, is one of 26 that started in 2015, is one of 202 in phase 2, and was the 169th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 26 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
AstraZeneca has 6 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
43 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 43 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis
This is a Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of MEDI9929 administered subcutaneously to adult subjects with moderate to severe Atopic Dermatitis. Subjects will be randomized in a 1:1 fashion and will be stratified at screening. Approximately 100 subjects are planned to be randomized at approximately 35 sites in 6 countries
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
Biological: MEDI9929
Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
Biological: Placebo
Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI 50) at Week 12
The eczema area and severity index (EASI) evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease. The EASI50 responder defined as a participant who achieved at least 50% reduction in EASI score from baseline.
Time frame: Baseline (Day 1) and Week 12
Percentage of Participants Achieving >= 75 % Reduction From Baseline in EASI75 at Week 12
The EASI evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease. The EASI75 responder defined as a participant who achieves at least a 75% reduction in EASI score from baseline.
Time frame: Baseline (Day 1) and Week 12
Mean Change From Baseline in EASI Total Score at Week 12
The EASI evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease.
Time frame: Baseline (Day 1) and Week 12
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 0 (Clear) or 1 (Almost Clear) and at Least a 2-Grade Reduction From Baseline
The investigator's global assessment (IGA) allows investigators to assess overall disease severity at one given time point and consists of a 5-point severity scale from clear to severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease). A participant has IGA response if they achieve a score of 0 (clear) or 1 (almost clear) and at least a 2-grade reduction from baseline.
Time frame: Baseline (Day 1) and Week 12
Mean Change From Baseline in the Scoring of Atopic Dermatitis (SCORAD) at Week 12
The scoring of atopic dermatitis (SCORAD) is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease.
Time frame: Baseline (Day 1) and Week 12
Percentage of Participants Achieving >= 50% Reduction From Baseline in SCORAD 50
The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease. The SCORAD 50 responder defined as a participant who achieves at least a 50% reduction in SCORAD score from baseline.
Time frame: Baseline (Day 1) and Week 12
Percentage of Participants Achieving >= 75% Reduction From Baseline in SCORAD 75
The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease. The SCORAD 75 responder is defined as a participant who achieves at least a 75% reduction in SCORAD score from baseline.
Time frame: Baseline (Day 1) and Week 12
Mean Change From Baseline in Average Pruritus Numeric Rating Scale (NRS) at Week 12
Pruritus is assessed using an Numeric Rating Scale (NRS) (0 - 10) with 0= no itch and 10= worst imaginable itch. Daily pruritus assessments were summarized as weekly peak score and a change from baseline in weekly peak score was calculated.
Time frame: Baseline (Day 1) and Week 12
Mean Change From Baseline in 5-D Pruritus Score at Week 12
The 5-D pruritus scale is a brief questionnaire designed to assess itch. This scale takes into account the multidimensional nature of pruritus, its impact on quality of life, and is capable of detecting change over time. The 5-D pruritus scale included 5 domains (duration, degree, direction, disability, and distribution of pruritus). The total 5-D score was obtained by scoring each of the domains separately and then summing them together. 5-D total scores ranged between 5 (no pruritus) and 25 (most severe pruritus). The higher values indicating more severe pruritus.
Time frame: Baseline (Day 1) and Week 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
An Adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of investigational product, whether or not considered related to investigational product. Serious adverse event is any AE that resulted in:death;inpatient hospitalization or prolongation of existing hospitalization;persistent or significant disability or incapacity;is life-threatening;is a congenital anomaly/birth defect in offspring of a study participant;or was an important medical event that may not have resulted in death, threatened life,or required hospitalization and that, based on appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent one of outcomes above. TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug until Week 22.
Time frame: From treatment administration (Day1) to 22 weeks
Mean Trough Serum Concentration of MEDI9929
The mean serum concentrations of MEDI9929 was observed at specified timepoints.
Time frame: Week 0 (Pre dose), Weeks 4, 8, and 12 (post dose)
Number of Participants Who Developed Detectable MEDI9929 Anti-drug Antibodies
A participant was considered ADA-positive across the study if they had a positive reading (titer of 50 or higher) at any time point during the study period.
Time frame: Baseline (Day 1) to Week 22
The study was conducted from 15Aug2015 to 15Jul2016.
| Milestone | Placebo | MEDI9929 280 mg |
|---|---|---|
| Started | 57 | 56 |
| Treated | 56 | 55 |
| Completed | 49 | 48 |
| Not completed | 8 | 8 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Withdrawal by subject | 5 | 6 |
| Withdrew: Not treated | 1 | 1 |
The eczema area and severity index (EASI) evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease. The EASI50 responder defined as a participant who achieved at least 50% reduction in EASI score from baseline.
| Percentage of participants | Placebo | MEDI9929 280 mg |
|---|---|---|
| Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI 50) at Week 12 | 48.2 | 64.7 |
The EASI evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease. The EASI75 responder defined as a participant who achieves at least a 75% reduction in EASI score from baseline.
| Percentage of participants | Placebo | MEDI9929 280 mg |
|---|---|---|
| Percentage of Participants Achieving >= 75 % Reduction From Baseline in EASI75 at Week 12 | 19.8 | 24.4 |
The EASI evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease.
| units on a scale | Placebo | MEDI9929 280 mg |
|---|---|---|
| Baseline | 24.48 ± 11.21 | 24.05 ± 12.38 |
| Week 12 | -11.23 ± 8.73 | -12.16 ± 9.96 |
The investigator's global assessment (IGA) allows investigators to assess overall disease severity at one given time point and consists of a 5-point severity scale from clear to severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease). A participant has IGA response if they achieve a score of 0 (clear) or 1 (almost clear) and at least a 2-grade reduction from baseline.
| Percentage of participants | Placebo | MEDI9929 280 mg |
|---|---|---|
| Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 0 (Clear) or 1 (Almost Clear) and at Least a 2-Grade Reduction From Baseline | 12.8 | 19.3 |
The scoring of atopic dermatitis (SCORAD) is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease.
| units on a scale | Placebo | MEDI9929 280 mg |
|---|---|---|
| Baseline | 58.66 ± 13.32 | 57.68 ± 14.80 |
| Week 12 | -19.35 ± 17.49 | -24.24 ± 16.94 |
The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease. The SCORAD 50 responder defined as a participant who achieves at least a 50% reduction in SCORAD score from baseline.
| Percentage of participants | Placebo | MEDI9929 280 mg |
|---|---|---|
| Percentage of Participants Achieving >= 50% Reduction From Baseline in SCORAD 50 | 29.4 | 41.0 |
The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease. The SCORAD 75 responder is defined as a participant who achieves at least a 75% reduction in SCORAD score from baseline.
| Percentage of participants | Placebo | MEDI9929 280 mg |
|---|---|---|
| Percentage of Participants Achieving >= 75% Reduction From Baseline in SCORAD 75 | 7.4 | 9.8 |
Pruritus is assessed using an Numeric Rating Scale (NRS) (0 - 10) with 0= no itch and 10= worst imaginable itch. Daily pruritus assessments were summarized as weekly peak score and a change from baseline in weekly peak score was calculated.
| units on a scale | Placebo | MEDI9929 280 mg |
|---|---|---|
| Baseline | 5.15 ± 2.10 | 5.26 ± 2.02 |
| Week 12 | -1.39 ± 1.93 | -1.90 ± 1.99 |
The 5-D pruritus scale is a brief questionnaire designed to assess itch. This scale takes into account the multidimensional nature of pruritus, its impact on quality of life, and is capable of detecting change over time. The 5-D pruritus scale included 5 domains (duration, degree, direction, disability, and distribution of pruritus). The total 5-D score was obtained by scoring each of the domains separately and then summing them together. 5-D total scores ranged between 5 (no pruritus) and 25 (most severe pruritus). The higher values indicating more severe pruritus.
| units on a scale | Placebo | MEDI9929 280 mg |
|---|---|---|
| Baseline | 16.7 ± 3.7 | 16.0 ± 3.7 |
| Week 12 | -3.9 ± 4.5 | -3.6 ± 4.4 |
An Adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of investigational product, whether or not considered related to investigational product. Serious adverse event is any AE that resulted in:death;inpatient hospitalization or prolongation of existing hospitalization;persistent or significant disability or incapacity;is life-threatening;is a congenital anomaly/birth defect in offspring of a study participant;or was an important medical event that may not have resulted in death, threatened life,or required hospitalization and that, based on appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent one of outcomes above. TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug until Week 22.
| Participants | Placebo | MEDI9929 280 mg |
|---|---|---|
| TEAEs | 40 | 38 |
| TESAEs | 3 | 2 |
The mean serum concentrations of MEDI9929 was observed at specified timepoints.
| mcg/mL | MEDI9929 280 mg |
|---|---|
| Week 0 | NA ± NA |
| Week 4 | 34.7 ± 10.9 |
| Week 8 | 50.5 ± 17.5 |
| Week 12 | 54.9 ± 21.5 |
A participant was considered ADA-positive across the study if they had a positive reading (titer of 50 or higher) at any time point during the study period.
| Participants | Placebo | MEDI9929 280 mg |
|---|---|---|
| Baseline | 2 | 1 |
| Week 22 | 2 | 0 |
Collected over From treatment administration (Day1) to 22 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/55 (5.5%) | 33/55 (60%) |
| MEDI9929 280 mg | — | 2/56 (3.6%) | 29/56 (51.8%) |
| Event | Placebo | MEDI9929 280 mg |
|---|---|---|
| Chest painGeneral disorders | 1/55 | 0/56 |
| CellulitisInfections and infestations | 1/55 | 0/56 |
| SyncopeNervous system disorders | 1/55 | 0/56 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 1/55 | 1/56 |
| Infected dermal cystInfections and infestations | 0/55 | 1/56 |
| Event | Placebo | MEDI9929 280 mg |
|---|---|---|
| NasopharyngitisInfections and infestations | 11/55 | 13/56 |
| Upper respiratory tract infectionInfections and infestations | 7/55 | 1/56 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 7/55 | 5/56 |
| DiarrhoeaGastrointestinal disorders | 3/55 | 5/56 |
| Injection site erythemaGeneral disorders | 0/55 | 3/56 |
| HeadacheNervous system disorders | 1/55 | 3/56 |
| CellulitisInfections and infestations | 2/55 | 0/56 |
| SinusitisInfections and infestations | 2/55 | 2/56 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/55 | 1/56 |
| RashSkin and subcutaneous tissue disorders | 2/55 | 0/56 |
Intent-To-Treat (ITT) population included all participants who were randomized and received any study investigational product.
| Age, Continuous(Years) | Placebo | MEDI9929 280 mg | Total |
|---|---|---|---|
| Mean | 38.8 ± 15.3 | 38.5 ± 14.9 | 38.7 ± 15.0 |
| Age, Customized(Participants) | Placebo | MEDI9929 280 mg | Total |
|---|---|---|---|
| 18-35 years | 28 | 27 | 55 |
| 36-75 years | 28 | 28 | 56 |
| Sex: Female, Male(Participants) | Placebo | MEDI9929 280 mg | Total |
|---|---|---|---|
| Female | 26 | 23 | 49 |
| Male | 30 | 32 | 62 |
| Eczema Area and Severity Index Score(Participants) | Placebo | MEDI9929 280 mg | Total |
|---|---|---|---|
| <= 25 points | 36 | 33 | 69 |
| > 25 points | 20 | 22 | 42 |
| Investigator's Global Assessment(Participants) | Placebo | MEDI9929 280 mg | Total |
|---|---|---|---|
| Category 2 | 0 | 1 | 1 |
| Category 3 | 46 | 44 | 90 |
| Category 4 | 10 | 10 | 20 |
| Atopic Dermatitis Status(Participants) | Placebo | MEDI9929 280 mg | Total |
|---|---|---|---|
| IgE >= 150 kU/L and Positive Serum Specific IgEa | 50 | 47 | 97 |
| IgE >= 150 kU/L and Negative Serum Specific IgE | 2 | 0 | 2 |
| IgE < 150 kU/L and Positive Serum Specific IgE | 3 | 3 | 6 |
| IgE < 150 kU/L and Negative Serum Specific IgEb | 1 | 3 | 4 |
| Missing | 0 | 2 | 2 |
Ran from Aug 2015 to primary completion in May 2016, 8 months.
Results were first posted in Feb 2018, 1 year 9 months after primary completion. A results delay was requested in Jun 2017.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 8 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tezepelumab